Irene Rossi is the Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company (UK). Irene obtained a MSc in Pharmaceutical Chemistry and Technology in 2014 and a PhD in Drugs, Biomolecules and Health Products at the Food and Drug Department, University of Parma (Italy) in 2019.
She joined Nanopharm in 2019 and she currently leads a group focused on the development of new technologies for OINDP products. Her main research area is the production, optimization and characterization of powders and liquid formulations for nasal and inhalation containing both small or large molecules.
Up to date, Irene has submitted and published 6 original papers, a patent application on the development of a dry powder for pulmonary vaccination and she presented her work at more than 20 international conferences